AI Article Synopsis
- Novel drugs have significantly improved outcomes for chronic lymphocytic leukemia (CLL) patients, challenging traditional prognostic factors from the chemotherapy era.
- Important genetic biomarkers for CLL now include the immunoglobulin heavy chain variable mutational status, genetic abnormalities like del(17p), and complex karyotypes.
- New scoring systems based on these genomic markers can help identify high-risk CLL patients, allowing for personalized treatment with targeted therapies that could enhance patient outcomes.
Article Abstract
Novel drugs have profoundly changed the outcomes in chronic lymphocytic leukemia (CLL) patients, and the traditional prognostic factors that were identified in the era of chemoimmunotherapy need to be validated in the context of these new targeted therapies. Currently, the most important prognostic genetic biomarkers are the immunoglobulin heavy chain variable () mutational status, genetic aberrations including del(17p)/ abnormalities, and the complex karyotype. In this review, we discuss the prognostic role of these genomic markers in relation to novel treatments. Moreover, we present and discuss new scoring systems that were elaborated and validated in the era of new drugs. In routine clinical practice, the application of an extensive genomic work-up with validated prognostic markers could improve the identification of "very high-risk" CLL patients who could benefit from novel, more effective targeted treatments.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11311700 | PMC |
| http://dx.doi.org/10.3390/cancers16152732 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cutaneous Involvement of the Ear as the Sole Presenting Symptom in Recurrent Chronic Lymphocytic Leukemia: A Case Report.
Ear Nose Throat J
January 2025
Department of Otolaryngology, Dartmouth Hitchcock Medical Center, Lebanon, NH, USA.
Cutaneous involvement of chronic lymphocytic leukemia (CLL) is rare but has been previously documented to involve the head and neck region. Generally, involvement to the ears is limited to the ear lobule; however, this study presents a unique case of recurrent CLL with cutaneous involvement overlying the auricular ear. The presentation was initially concerning for possible perichondritis but remained unresponsive to antibiotics and steroids.
View Article and Find Full Text PDFAberrant c-AMP signalling in richter syndrome revealed by single-cell transcriptome and 3D chromatin analysis.
Biomark Res
January 2025
Department of Hematology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Richter syndrome (RS), characterized by aggressive lymphoma arising from chronic lymphocytic leukaemia (CLL), presents a poor response to treatment and grim prognosis. To elucidate RS mechanisms, paired samples from a patient with DLBCL-RS were subjected to single-cell RNA sequencing (scRNA-seq) and high-throughput chromosome conformation capture (Hi-C) sequencing. Over 10,000 cells were profiled via scRNA-seq, revealing the comprehensive B cell transformation in RS.
View Article and Find Full Text PDFMonocyte STAT1 phosphorylation and treatment response of JAK inhibitors in chronic nonbacterial osteomyelitis.
Pediatr Rheumatol Online J
January 2025
Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan.
Background: Chronic nonbacterial osteomyelitis (CNO) is a rare autoinflammatory disease of unknown cause, predominantly affecting teens and young adults. The early diagnosis and management are challenging due to the lack of reliable diagnostic markers and the occasional intractable cases despite conventional anti-inflammatory treatments. Janus kinase (JAK) inhibitors have recently shown potential utility; however, reports on their use for pediatric patients with CNO remain limited, and no established biomarkers exist to monitor disease activity.
View Article and Find Full Text PDFMultiplex digital PCR enables sensitive detection of resistance to BTK inhibitors.
Ann Hematol
January 2025
Service de Thérapie Cellulaire et d'Hématologie Clinique, CHU Estaing, Clermont-Ferrand, France.
The advent of BTK inhibitors has been transformative in the management of patients with chronic lymphocytic leukemia or other B-cell lymphoproliferative disorders. However, emergence of BTK or PLCG2 mutations lead to resistance to these compounds and are now a growing concern in clinical practice. Assessing BTK mutations is now becoming a priority to guide the therapeutic decision at further relapse.
View Article and Find Full Text PDFAssociations between brominated flame retardants exposure and non-alcoholic fatty liver disease: Mediation analysis in the NHANES.
Ecotoxicol Environ Saf
January 2025
Department of Occupational Medicine and Environmental Toxicology, Nantong Key Laboratory of Environmental Toxicology, School of Public Health, Nantong University, Nantong 226019, China. Electronic address:
Background: Exposure to brominated flame retardants (BFRs) may negatively impact human health. The association of BFRs with nonalcoholic fatty liver disease (NAFLD) in the general population is unclear. Meanwhile, limited studies have investigated the potential role of oxidative stress and inflammation in this link.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!